Regeneron Pharmaceuticals (REGN) Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $3.6 billion for Q1 2026.

• In Q1 2026, Revenue rose 19.04% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $14.9 billion (up 5.92% YoY), while the FY2025 annual figure was $14.3 billion, up 0.99% from the prior year.
• Revenue was $3.6 billion for Q1 2026 at Regeneron Pharmaceuticals, down from $3.9 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $3.9 billion in Q4 2025 to a low of $50.0 million in Q1 2022.
• Historically, Revenue has averaged $3.0 billion across 5 years, with a median of $3.4 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Revenue slumped 98.02% in 2022, then jumped 6224.2% in 2023.
• A 5-year view of Revenue shows it stood at $100.0 million in 2022, then surged by 3334.3% to $3.4 billion in 2023, then gained by 10.33% to $3.8 billion in 2024, then gained by 2.51% to $3.9 billion in 2025, then declined by 7.18% to $3.6 billion in 2026.
• The last three Revenue figures came in at $3.6 billion (Q1 2026), $3.9 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.